🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

This Study is a Prospective, Multi-center, Real World, Observational Study, Which Aims at Evaluating Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease.

Recruitingn/aAges 18 Years - 80 YearsAllShanghai Zhongshan Hospital
NCT05391815 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a prospective, multi-center, real world, observational study, which aims at evaluating the intermediate and long-term efficacy of endovascular treatment for TASC C\&D aortoiliac occlusive disease .It is estimated that 800 subjects diagnosed with TASC C\&D aortoiliac occlusive disease and receive endovascular treatments will be enrolled in nine centers from April 2021 to June 2027 nation-widely. All the subjects will be under follow-up for 60 months. There is no restriction on the endovascular techniques. The primary outcomes covers freedom from TLR at 60 months.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Rutherford grades 3-6. 2. Follow the follow-up arrangement. 3. Age: 18-80 years old. 4. The target lesions were in the lower abdominal aorta and/or the common iliac artery and/or the external iliac artery. 5. The stenosis degree ≥50%, or restenosis (received PTA or other adjuvant therapy, including bare or covers stents), or complete occlusion, or the presence of aortailiac artery thrombosis after PMT or CDT thrombus clearance, and then further endovascular therapy perfomred. 6. Signed informed consent. Exclusion Criteria: 1. Known allergy to drugs used in this study, including antiplatelet or anticoagulant drugs, etc. 2. Allergy to iodine contrast agent allergy; 3. Coagulation dysfunction or hypercoagulability; 4. Breast-feeding or pregnant women; 5. Life expectancy \< 24 months; 6. Body condition can not tolerate endovascular treatment; 7. Type 2B, type 3 lower limb ischemia patients
💊

What it tests

  • Not listed
📍

Where

1 site
Zhongshan Hospital, Fudan University
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy